GlassScriptPhysician profile
Dana Andreo
NPI 1801377502
$4,240.31
in general payments reported to CMS, 2019-2025
25 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $904 · 2023: $1,708 · 2024: $811 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.15 | 2021-2024 | |
| Boston Scientific Corporation | $678.34 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $599.69 | 2022-2024 | Relistor |
| Scilex Pharmaceuticals INC. | $398.48 | 2021-2024 | Ztlido |
| Azurity Pharmaceuticals, INC. | $245.55 | 2023-2024 | Horizant, Horizant |
| Collegium Pharmaceutical, INC. | $219.08 | 2023-2024 | Xtampza, Belbuca |
| Ibsa Pharma INC. | $154.81 | 2023-2024 | Tirosint, Licart, Tirosint |
| Merz Pharmaceuticals, LLC | $136.17 | 2021-2024 | Xeomin |
| Pfizer INC. | $125.01 | 2023-2024 | |
| Medtronic, INC. | $116.05 | 2023-2024 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $106.52 | 2021-2022 | |
| Redhill Biopharma INC. | $88.36 | 2021 | |
| Valinor Pharma, LLC | $74.05 | 2023-2024 | Movantik |
| Ipsen Biopharmaceuticals, INC | $72.49 | 2023-2024 | Dysport |
| Grt US Holding, INC. | $66.24 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $56.04 | 2021-2023 | Gralise |
| Nevro Corp. | $34.65 | 2021-2023 | Senza |
| Neurometrix INC | $32.44 | 2023 | |
| Vertos Medical, INC. | $31.04 | 2024 | Mild Device Kit |
| Allergan, INC. | $24.09 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.05 | 2023 | |
| Averitas Pharma INC. | $20.27 | 2024 | Qutenza |
| Nalu Medical, INC. | $14.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.11 | 2021 | |
| Tersera Therapeutics LLC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Andreo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.